57526-81-5

Usage

Uses

Used in Pharmaceutical Industry:
Prenalterol is used as a cardiotonic agent for the treatment of heart failure and other conditions that require the enhancement of cardiac contractility. Its primary application is in the management of congestive heart failure, where it helps improve the heart's ability to pump blood effectively, thereby alleviating symptoms and improving the patient's quality of life.
Additionally, Prenalterol may be used in the treatment of certain arrhythmias, where its ability to increase heart rate can help regulate the rhythm of the heartbeat. Furthermore, it may also be utilized in the management of acute myocardial infarction (heart attack) to support the heart's function during the critical period following the event.

InChI:InChI=1/C12H19NO3/c1-9(2)13-7-11(15)8-16-12-5-3-10(14)4-6-12/h3-6,9,11,13-15H,7-8H2,1-2H3

Upstream product

• 57526-82-6 (2S)-1-<4-(benzyloxy)phenoxy>-3-<(1-methylethyl)amino>-2-propanol 
• 103-16-2 4-Benzyloxyphenol 
• 68430-29-5 (S)-5-hydroxymethyl-3-(methylethyl)oxazolidinone 
• 68430-35-3 (S)-3-isopropyl-5-p-toluenesulfonyloxymethyl-oxazolidin-2-one 
• 86955-00-2 (S)-N-isopropyl-2,3-O-isopropylidene-D-glyceraldimine 
• 72223-70-2 (4S)-2,2-dimethyl-4-<<(1-methylethyl)(methylsulfonyl)amino>methyl>-1,3-dioxolane 
• 68430-26-2 [2S]-O-isopropylidene-3-isopropylamino-1,2-propanediol 
• 72223-71-3 (2S)-3-<(1-methylethyl)(methylsulfonyl)amino>-1,2-propanediol 
• 86955-02-4 (2S)-N-(1-methylethyl)-N-(methylsulfonyl)oxiranemethanamine 
• 86955-01-3 Acetic acid (S)-1-chloromethyl-2-(isopropyl-methanesulfonyl-amino)-ethyl ester 
• 72223-74-6 N-Isopropyl-N-((S)-2-methoxy-2-methyl-[1,3]dioxolan-4-ylmethyl)-methanesulfonamide 
• 72223-78-0 (2S)-1-<4-(benzyloxy)phenoxy>-3-<(1-methylethyl)(methylsulfonyl)amino>-2-propanol 
• 75-31-0 isopropylamine 
• 730984-83-5 (S)-4-(2,3-epoxypropoxy)phenol 

Downstream Products

• 86955-34-2 (S)-1-(4-{8-[4-((S)-2-Hydroxy-3-isopropylamino-propoxy)-phenoxy]-octyloxy}-phenoxy)-3-isopropylamino-propan-2-ol 
• 86955-37-5 (S)-1-(4-{12-[4-((S)-2-Hydroxy-3-isopropylamino-propoxy)-phenoxy]-dodecyloxy}-phenoxy)-3-isopropylamino-propan-2-ol 
• 86955-39-7 (S)-1-(4-{14-[4-((S)-2-Hydroxy-3-isopropylamino-propoxy)-phenoxy]-tetradecyloxy}-phenoxy)-3-isopropylamino-propan-2-ol 
• 86955-41-1 (S)-1-(4-{20-[4-((S)-2-Hydroxy-3-isopropylamino-propoxy)-phenoxy]-icosyloxy}-phenoxy)-3-isopropylamino-propan-2-ol 
• 86901-76-0 (S)-1-[4-(2-{2-[4-((S)-2-Hydroxy-3-isopropylamino-propoxy)-phenoxy]-ethoxy}-ethoxy)-phenoxy]-3-isopropylamino-propan-2-ol 
• 86955-28-4 (S)-1-(4-{2-[2-(2-{2-[4-((S)-2-Hydroxy-3-isopropylamino-propoxy)-phenoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-phenoxy)-3-isopropylamino-propan-2-ol 
• 86955-35-3 (S)-1-(4-{10-[4-((S)-2-Hydroxy-3-isopropylamino-propoxy)-phenoxy]-decyloxy}-phenoxy)-3-isopropylamino-propan-2-ol 
• 84057-96-5 flusoxolol 
• 86955-43-3 (S)-1-{4-[2-(2-{2-[4-((S)-2-Hydroxy-3-isopropylamino-propoxy)-phenoxy]-ethoxy}-ethoxy)-ethoxy]-phenoxy}-3-isopropylamino-propan-2-ol 

Relevant academic research and scientific papers

Effective synthesis of non-racemic prenalterol based on spontaneous resolution of 3-(4-hydroxyphenoxy)propane-1,2-diol

Spontaneous resolution of rac-3-(4-hydroxyphenoxy)propane-1,2-diol has been successfully used in the synthesis of both enantiomers of chiral drug prenalterol.

METHODS FOR DIAGNOSING, MONITORING AND TREATING NEUROLOGICAL DISEASES AND DISORDERS

In various aspects and embodiments provided are compositions and methods for identifying patients in need of improving cognition and/or treating a neurodegenerative disease in a patient and treating such patient.

Substituted (10H-phenothiazin-10-L)-propyl-1-piperazines

Substituted (10H-phenothiazin-10-yl)propyl-1-piperazines of the formula STR1 wherein R1, R2, R3, A, X, m, n and s are as hereinafter set forth, are described. The compounds of formula I, which contain a piperazine moiety combined by an ether linkage to different phenolic moieties, are useful as orally active long lasting antipsychotic agents.

β1-Selective Adrenoceptor Antagonists. 1. Synthesis and β-Adrenergic Blocking Activity of a Series of Binary (Aryloxy)propanolamines

A series of binary (aryloxy)propanolamines has been prepared and examined in vitro and in vivo for β-adrenoreceptor blocking activity.These symmetrical compounds consist of two (S)-(phenyloxy)propanolamine pharmacophores coupled through alkylenedioxy or poly(oxyethylenedioxy) linking units of varying lengths.Examples of such binary compounds linked through the 2,2', 3,3', and 4,4' positions in the aromatic rings of the pharmacophores have been prepared.In vitro and in vivo test data indicate that the 2,2' compounds tend to be selective β2-adrenergic blocking agents, the 4,4' binaries tend to be selective β1-blocking agents, and those compounds with 3,3' linkages exhibit intermediate selectivities.One of the 4,4'-linked binary compounds, 4s, exhibited potent, cardioselective β-blockade in vivo, which was of short duration and was accompanied by a prolonged tachycardia.

(S)-1-[2-(4-HYDROXY-S-(1-ALKYLAMINO-PROPOXY)PHENYLALKYL]-4-PHENYLPIPERAZINES

There are disclosed compounds of the formula STR1 wherein R 1 is selected from the group consisting of lower alkyl; R 8 is selected from the group consisting of--O--(CH 2) n--wherein n is 2 to 20, STR2 and R 6 is selected from the group consisting of hydrogen or lower alkoxy, and STR3 wherein R 1 is selected from the group consisting of lower alkyl; R 8 is selected from the group consisting of--O--(CH 2) n--wherein n is 2 to 20, STR4 and R 6 is selected from the group consisting of hydrogen or lower alkoxy and racemates thereof.There are also disclosed processes and intermediates utilized to produce the end products. The end products have utility as agents exhibiting both α and selective β adrenergic blocking action.

Phenoxy substituted glycosides

1-Phenoxy-2-hydroxy-3-amino-propanes of the formula I EQU1 wherein R1 is a sugar residue and R2 is isopropyl, tert.-butyl or α-methyl-phenethyl optionally substituted in the phenyl part, and the salts thereof are useful as positively inotropic agents, especially in the treatment of insufficiency of the cardiac muscle.